FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Appl Environ Microbiol / Use of a bacteriophage lysin, PlyC, as an enzyme disinfectan...
Applied and environmental microbiology2009; 75(5); 1388-1394; doi: 10.1128/AEM.02195-08

Use of a bacteriophage lysin, PlyC, as an enzyme disinfectant against Streptococcus equi.

Abstract: Streptococcus equi is the causative agent of the purulent infection equine strangles. This disease is transmitted through shedding of live bacteria from nasal secretions and abscess drainage or by contact with surfaces contaminated by the bacteria. Disinfectants are effective against S. equi, but inactivation by environmental factors, damage to equipment, and toxicity are of great concern. Bacteriophage-encoded lysins (cell wall hydrolases) have been investigated as therapeutic agents due to their ability to lyse susceptible gram-positive organisms. Here, we investigate the use of one lysin, PlyC, as a narrow-spectrum disinfectant against S. equi. This enzyme was active against >20 clinical isolates of S. equi, including both S. equi subsp. equi and S. equi subsp. zooepidemicus. Significantly, PlyC was 1,000 times more active on a per weight basis than Virkon-S, a common disinfecting agent, with 1 microg of enzyme able to sterilize a 10(8) CFU/ml culture of S. equi in 30 min. PlyC was subjected to a standard battery of tests including the Use Dilution Method for Testing Disinfectants and the Germicidal Spray Products Test. Results indicate that aerosolized PlyC can eradicate or significantly reduce the S. equi load on a variety of materials found on common stable and horse-related equipment. Additionally, PlyC was shown to retain full activity under conditions that mimic a horse stable, i.e., in the presence of nonionic detergents, hard water, or organic materials. We propose PlyC as the first protein-based, narrow-spectrum disinfectant against S. equi, which may augment or supplement the use of broad-spectrum disinfectants in barns and stables where equine strangles is prevalent.
Get Full Text
Publication Date: 2009-01-09 PubMed ID: 19139235PubMed Central: PMC2648168DOI: 10.1128/AEM.02195-08Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article explores the use of PlyC, a bacteriophage lysin, as a disinfectant against Streptococcus equi, the agent that causes the serious equine disease, equine strangles. The study found that PlyC was significantly more effective than an existing common disinfectant and retained its potency under conditions mimicking a horse stable.

Objective of the research

  • The main aim of this research was to investigate the effectiveness of PlyC – a kind of bacteriophage lysin – as a disinfectant against Streptococcus equi. This bacterium causes equine strangles, a highly contagious and serious infection in horses that is challenging to control due to the bacteria’s ability to survive on surfaces and in the environment.

Methods used

  • The research team tested PlyC’s impact on over 20 clinical isolates of S. equi, including both S. equi subsp. equi and S. equi subsp. zooepidemicus.
  • The effectiveness of PlyC was compared to that of Virkon-S, a common disinfecting agent. The comparison was made on a per weight basis.
  • PlyC was subjected to tests including the Use Dilution Method for Testing Disinfectants and the Germicidal Spray Products Test to ensure reliability.

Findings from the research

  • The research found that PlyC was highly effective against S. equi. Remarkably, it was 1,000 times more active on a per weight basis than Virkon-S.
  • Even just 1 microgram of PlyC was able to completely sterilize a culture of S. equi in 30 minutes.
  • Results suggested that PlyC in an aerosolized form could either substantially reduce or completely eradicate the S. equi load on different materials commonly found on stable and horse-related equipment.
  • PlyC also retained its full activity under conditions that replicate those of a horse stable, such as in the presence of nonionic detergents, hard water, or organic materials.

Implications of the research

  • PlyC could offer a new protein-based, narrow-spectrum disinfectant option against S. equi. This may supplement or replace the use of broad-spectrum disinfectants in barns and stables where equine strangles is prevalent, potentially improving the control of this serious disease.

Cite This Article

APA
Hoopes JT, Stark CJ, Kim HA, Sussman DJ, Donovan DM, Nelson DC. (2009). Use of a bacteriophage lysin, PlyC, as an enzyme disinfectant against Streptococcus equi. Appl Environ Microbiol, 75(5), 1388-1394. https://doi.org/10.1128/AEM.02195-08

Publication

Applied and environmental microbiology
ISSN: 1098-5336
NlmUniqueID: 7605801
Country: United States
Language: English
Volume: 75
Issue: 5
Pages: 1388-1394

Researcher Affiliations

Hoopes, J Todd
  • Center for Advanced Research in Biotechnology, University of Maryland Biotechnology Institute, Rockville, Maryland 20850, USA.
Stark, Caren J
    Kim, Han Ah
      Sussman, Daniel J
        Donovan, David M
          Nelson, Daniel C

            MeSH Terms

            • Animals
            • Bacteriophages / enzymology
            • Colony Count, Microbial
            • Disinfectants / pharmacology
            • Microbial Viability
            • Mucoproteins / pharmacology
            • Streptococcus equi / drug effects
            • Time Factors
            • Viral Proteins / pharmacology

            References

            This article includes 29 references
            1. AOAC International. AOAC official method 960.09. .
            2. AOAC International. AOAC germicidal spray products test, official method 961.02. .
            3. AOAC International. Use dilution methods for testing disinfectants, official methods 955.15 and 964.02. .
            4. Barnham M, Cole G, Efstratiou A, Tagg JR, Skjold SA. Characterization of Streptococcus zooepidemicus (Lancefield group C) from human and selected animal infections.. Epidemiol Infect 1987 Apr;98(2):171-82.
              pmc: PMC2235236pubmed: 3556444doi: 10.1017/s0950268800061884google scholar: lookup
            5. Blanchard PC, Fiser KM. Streptococcus dysgalactiae polyarthritis in dairy goats.. J Am Vet Med Assoc 1994 Sep 1;205(5):739-41.
              pubmed: 7989246
            6. Boothe HW. Antiseptics and disinfectants.. Vet Clin North Am Small Anim Pract 1998 Mar;28(2):233-48.
              pubmed: 9556847doi: 10.1016/s0195-5616(98)82003-2google scholar: lookup
            7. Duan Y, Dinehart K, Hickey J, Panicucci R, Kessler J, Gottardi W. Properties of an enzyme-based low-level iodine disinfectant.. J Hosp Infect 1999 Nov;43(3):219-29.
              pubmed: 10582189doi: 10.1053/jhin.1999.0249google scholar: lookup
            8. Dvorak G. Disinfection 101. .
            9. Dwyer RM. Disinfecting equine facilities.. Rev Sci Tech 1995 Jun;14(2):403-18.
              pubmed: 7579639doi: 10.20506/rst.14.2.846google scholar: lookup
            10. Dwyer RM. Environmental disinfection to control equine infectious diseases.. Vet Clin North Am Equine Pract 2004 Dec;20(3):531-42.
              pubmed: 15519816doi: 10.1016/j.cveq.2004.07.001google scholar: lookup
            11. Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives.. Trends Microbiol 2005 Oct;13(10):491-6.
              pubmed: 16125935doi: 10.1016/j.tim.2005.08.007google scholar: lookup
            12. Fischetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum?. Nat Biotechnol 2006 Dec;24(12):1508-11.
              pubmed: 17160051doi: 10.1038/nbt1206-1508google scholar: lookup
            13. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis.. J Infect Dis 2008 Jun 1;197(11):1519-22.
              pubmed: 18471063doi: 10.1086/587942google scholar: lookup
            14. Hansen EH, Albertsen L, Schäfer T, Johansen C, Frisvad JC, Molin S, Gram L. Curvularia haloperoxidase: antimicrobial activity and potential application as a surface disinfectant.. Appl Environ Microbiol 2003 Aug;69(8):4611-7.
              pmc: PMC169116pubmed: 12902249doi: 10.1128/aem.69.8.4611-4617.2003google scholar: lookup
            15. Harrington DJ, Sutcliffe IC, Chanter N. The molecular basis of Streptococcus equi infection and disease.. Microbes Infect 2002 Apr;4(4):501-10.
              pubmed: 11932201doi: 10.1016/s1286-4579(02)01565-4google scholar: lookup
            16. Herńndez A, Martró E, Matas L, Martín M, Ausina V. Assessment of in-vitro efficacy of 1% Virkon against bacteria, fungi, viruses and spores by means of AFNOR guidelines.. J Hosp Infect 2000 Nov;46(3):203-9.
              pubmed: 11073729doi: 10.1053/jhin.2000.0818google scholar: lookup
            17. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.. Science 2001 Dec 7;294(5549):2170-2.
              pubmed: 11739958doi: 10.1126/science.1066869google scholar: lookup
            18. Loessner MJ, Kramer K, Ebel F, Scherer S. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates.. Mol Microbiol 2002 Apr;44(2):335-49.
              pubmed: 11972774doi: 10.1046/j.1365-2958.2002.02889.xgoogle scholar: lookup
            19. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme.. Proc Natl Acad Sci U S A 2001 Mar 27;98(7):4107-12.
              pmc: PMC31187pubmed: 11259652doi: 10.1073/pnas.061038398google scholar: lookup
            20. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. PlyC: a multimeric bacteriophage lysin.. Proc Natl Acad Sci U S A 2006 Jul 11;103(28):10765-70.
              pmc: PMC1487170pubmed: 16818874doi: 10.1073/pnas.0604521103google scholar: lookup
            21. Randall LP, Cooles SW, Coldham NG, Penuela EG, Mott AC, Woodward MJ, Piddock LJ, Webber MA. Commonly used farm disinfectants can select for mutant Salmonella enterica serovar Typhimurium with decreased susceptibility to biocides and antibiotics without compromising virulence.. J Antimicrob Chemother 2007 Dec;60(6):1273-80.
              pubmed: 17897935doi: 10.1093/jac/dkm359google scholar: lookup
            22. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Yagyu K, Muraoka A, Sugai M, Hiramatsu K, Honke K, Matsuzaki S. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11.. J Infect Dis 2007 Oct 15;196(8):1237-47.
              pubmed: 17955443doi: 10.1086/521305google scholar: lookup
            23. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis.. Nature 2002 Aug 22;418(6900):884-9.
              pubmed: 12192412doi: 10.1038/nature01026google scholar: lookup
            24. Sweeney CR, Timoney JF, Newton JR, Hines MT. Streptococcus equi infections in horses: guidelines for treatment, control, and prevention of strangles.. J Vet Intern Med 2005 Jan-Feb;19(1):123-34.
              pubmed: 15715061
            25. Sweeney CR, Whitlock RH, Meirs DA, Whitehead SC, Barningham SO. Complications associated with Streptococcus equi infection on a horse farm.. J Am Vet Med Assoc 1987 Dec 1;191(11):1446-8.
              pubmed: 3692991
            26. Traub-Dargatz JL, Dargatz DA, Morley PS, Dunowska M. An overview of infection control strategies for equine facilities, with an emphasis on veterinary hospitals.. Vet Clin North Am Equine Pract 2004 Dec;20(3):507-20, v.
              pubmed: 15519814doi: 10.1016/j.cveq.2004.07.004google scholar: lookup
            27. Valberg SJ, Bullock P, Hogetvedt W, Ames T, Hayden DW, Ott K. Myopathies associated with Streptococcus equi infections in horses. Proc. Am. Assoc. Equine Pract. 42:292-293.
            28. Waage S, Mørk T, Røros A, Aasland D, Hunshamar A, Odegaard SA. Bacteria associated with clinical mastitis in dairy heifers.. J Dairy Sci 1999 Apr;82(4):712-9.
              pubmed: 10212457doi: 10.3168/jds.s0022-0302(99)75288-4google scholar: lookup
            29. Waller AS, Jolley KA. Getting a grip on strangles: recent progress towards improved diagnostics and vaccines.. Vet J 2007 May;173(3):492-501.
              pubmed: 16820310doi: 10.1016/j.tvjl.2006.05.011google scholar: lookup

            Citations

            This article has been cited 31 times.
            1. Liu Y, Zhao Y, Qian C, Huang Z, Feng L, Chen L, Yao Z, Xu C, Ye J, Zhou T. Study of Combined Effect of Bacteriophage vB3530 and Chlorhexidine on the Inactivation of Pseudomonas aeruginosa. BMC Microbiol 2023 Sep 13;23(1):256.
              doi: 10.1186/s12866-023-02976-wpubmed: 37704976google scholar: lookup
            2. Osei EK, Mahony J, Kenny JG. From Farm to Fork: Streptococcus suis as a Model for the Development of Novel Phage-Based Biocontrol Agents. Viruses 2022 Sep 9;14(9).
              doi: 10.3390/v14091996pubmed: 36146802google scholar: lookup
            3. Wong KY, Megat Mazhar Khair MH, Song AA, Masarudin MJ, Chong CM, In LLA, Teo MYM. Endolysins against Streptococci as an antibiotic alternative. Front Microbiol 2022;13:935145.
              doi: 10.3389/fmicb.2022.935145pubmed: 35983327google scholar: lookup
            4. Asma ST, Imre K, Morar A, Herman V, Acaroz U, Mukhtar H, Arslan-Acaroz D, Shah SRA, Gerlach R. An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents. Life (Basel) 2022 Jul 23;12(8).
              doi: 10.3390/life12081110pubmed: 35892912google scholar: lookup
            5. Harhala MA, Gembara K, Nelson DC, Miernikiewicz P, Dąbrowska K. Immunogenicity of Endolysin PlyC. Antibiotics (Basel) 2022 Jul 18;11(7).
              doi: 10.3390/antibiotics11070966pubmed: 35884219google scholar: lookup
            6. Danis-Wlodarczyk KM, Wozniak DJ, Abedon ST. Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. Antibiotics (Basel) 2021 Dec 6;10(12).
              doi: 10.3390/antibiotics10121497pubmed: 34943709google scholar: lookup
            7. Cater K, Międzybrodzki R, Morozova V, Letkiewicz S, Łusiak-Szelachowska M, Rękas J, Weber-Dąbrowska B, Górski A. Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections. Antibiotics (Basel) 2021 Aug 24;10(9).
              doi: 10.3390/antibiotics10091030pubmed: 34572612google scholar: lookup
            8. Mitchell SJ, Verma D, Griswold KE, Bailey-Kellogg C. Building blocks and blueprints for bacterial autolysins. PLoS Comput Biol 2021 Apr;17(4):e1008889.
              doi: 10.1371/journal.pcbi.1008889pubmed: 33793553google scholar: lookup
            9. Abdelrahman F, Easwaran M, Daramola OI, Ragab S, Lynch S, Oduselu TJ, Khan FM, Ayobami A, Adnan F, Torrents E, Sanmukh S, El-Shibiny A. Phage-Encoded Endolysins. Antibiotics (Basel) 2021 Jan 28;10(2).
              doi: 10.3390/antibiotics10020124pubmed: 33525684google scholar: lookup
            10. Allué-Guardia A, Saranathan R, Chan J, Torrelles JB. Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis. Int J Mol Sci 2021 Jan 13;22(2).
              doi: 10.3390/ijms22020735pubmed: 33450990google scholar: lookup
            11. Love MJ, Bhandari D, Dobson RCJ, Billington C. Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care. Antibiotics (Basel) 2018 Feb 27;7(1).
              doi: 10.3390/antibiotics7010017pubmed: 29495476google scholar: lookup
            12. Haddad Kashani H, Schmelcher M, Sabzalipoor H, Seyed Hosseini E, Moniri R. Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies. Clin Microbiol Rev 2018 Jan;31(1).
              doi: 10.1128/CMR.00071-17pubmed: 29187396google scholar: lookup
            13. Akami M, Chakira H, Andongma AA, Khaeso K, Gbaye OA, Nicolas NY, Nukenine EN, Niu CY. Essential oil optimizes the susceptibility of Callosobruchus maculatus and enhances the nutritional qualities of stored cowpea Vigna unguiculata. R Soc Open Sci 2017 Aug;4(8):170692.
              doi: 10.1098/rsos.170692pubmed: 28879012google scholar: lookup
            14. Ajuebor J, McAuliffe O, O'Mahony J, Ross RP, Hill C, Coffey A. Bacteriophage endolysins and their applications. Sci Prog 2016 Jun 1;99(2):183-199.
              doi: 10.3184/003685016X14627913637705pubmed: 28742472google scholar: lookup
            15. Borkotoky S, Murali A. A computational assessment of pH-dependent differential interaction of T7 lysozyme with T7 RNA polymerase. BMC Struct Biol 2017 May 25;17(1):7.
              doi: 10.1186/s12900-017-0077-9pubmed: 28545576google scholar: lookup
            16. Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence 2018 Jan 1;9(1):522-554.
              doi: 10.1080/21505594.2017.1313372pubmed: 28362216google scholar: lookup
            17. Sharma AK, Kumar S, K H, Dhakan DB, Sharma VK. Prediction of peptidoglycan hydrolases- a new class of antibacterial proteins. BMC Genomics 2016 May 27;17:411.
              doi: 10.1186/s12864-016-2753-8pubmed: 27229861google scholar: lookup
            18. Tang F, Li D, Wang H, Ma Z, Lu C, Dai J. Prophage lysin Ply30 protects mice from Streptococcus suis and Streptococcus equi subsp. zooepidemicus infections. Appl Environ Microbiol 2015 Nov;81(21):7377-84.
              doi: 10.1128/AEM.02300-15pubmed: 26253669google scholar: lookup
            19. Trudil D. Phage lytic enzymes: a history. Virol Sin 2015 Feb;30(1):26-32.
              doi: 10.1007/s12250-014-3549-0pubmed: 25662888google scholar: lookup
            20. Lood R, Raz A, Molina H, Euler CW, Fischetti VA. A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia. Antimicrob Agents Chemother 2014 Jun;58(6):3073-84.
              doi: 10.1128/AAC.00115-14pubmed: 24637688google scholar: lookup
            21. Klumpp J, Loessner MJ. Listeria phages: Genomes, evolution, and application. Bacteriophage 2013 Jul 1;3(3):e26861.
              doi: 10.4161/bact.26861pubmed: 24251077google scholar: lookup
            22. Gervasi T, Horn N, Wegmann U, Dugo G, Narbad A, Mayer MJ. Expression and delivery of an endolysin to combat Clostridium perfringens. Appl Microbiol Biotechnol 2014 Mar;98(6):2495-505.
              doi: 10.1007/s00253-013-5128-ypubmed: 23942878google scholar: lookup
            23. Fenton M, Keary R, McAuliffe O, Ross RP, O'Mahony J, Coffey A. Bacteriophage-Derived Peptidase CHAP(K) Eliminates and Prevents Staphylococcal Biofilms. Int J Microbiol 2013;2013:625341.
              doi: 10.1155/2013/625341pubmed: 23431312google scholar: lookup
            24. Roach DR, Khatibi PA, Bischoff KM, Hughes SR, Donovan DM. Bacteriophage-encoded lytic enzymes control growth of contaminating Lactobacillus found in fuel ethanol fermentations. Biotechnol Biofuels 2013 Feb 7;6(1):20.
              doi: 10.1186/1754-6834-6-20pubmed: 23390890google scholar: lookup
            25. Potera C. Phage renaissance: new hope against antibiotic resistance. Environ Health Perspect 2013 Feb;121(2):a48-53.
              doi: 10.1289/ehp.121-a48pubmed: 23380024google scholar: lookup
            26. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 2012 Oct;7(10):1147-71.
              doi: 10.2217/fmb.12.97pubmed: 23030422google scholar: lookup
            27. Fenton M, Ross P, McAuliffe O, O'Mahony J, Coffey A. Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs 2010 Jan-Feb;1(1):9-16.
              doi: 10.4161/bbug.1.1.9818pubmed: 21327123google scholar: lookup
            28. Subramanyam B, Kumar V, Perumal V, Nagamiah S. Phage lysin to supplement phagebiotics to decontaminate processed sputum specimens. Eur J Clin Microbiol Infect Dis 2010 Nov;29(11):1407-12.
              doi: 10.1007/s10096-010-1018-8pubmed: 20652718google scholar: lookup
            29. Díaz B, Córdova P, Zamorano A, Alegría-Arcos M, Blondel CJ, Gamboa C, Fiore N, Tobar N, Ilabaca-Díaz C, Bertaccini A, Higuera G. Antimicrobial Activity of LysX and LysP Endolysins Against Pseudomonas syringae pv. syringae and Xanthomonas arboricola pv. juglandis. Plants (Basel) 2026 Jan 30;15(3).
              doi: 10.3390/plants15030431pubmed: 41681595google scholar: lookup
            30. Liu H, Sun L, Sun Q, Zhang S, Wang R. Characterization of LysBM1, a novel high-penetrating phage lysin targeting enterohemorrhagic Escherichia coli. Front Vet Sci 2025;12:1631293.
              doi: 10.3389/fvets.2025.1631293pubmed: 40717919google scholar: lookup
            31. Sabur A, Khan A, Borphukan B, Razzak A, Salimullah M, Khatun M. The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier. J Xenobiot 2025 Jan 25;15(1).
              doi: 10.3390/jox15010019pubmed: 39997362google scholar: lookup
            Subscribe to our newsletter
            Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.